COMPUMEDICS LIMITED — Regulatory Filings 2009

Jun 14, 2009

==> picture [76 x 80] intentionally omitted <==

ASX / MEDIA RELEASE

Compumedics Limited builds on its German direct sell strategy

Melbourne Australia, Monday 15 June, 2009

Leading medical devices company, Compumedics Limited (ASX:CMP) today announced the achievement of a further major milestone for its newly established Germany based sleep business after winning an additional $300k in two further prestigious sleepdiagnostics devices contracts.

Germany is the world’s third largest medical device market and Europe’s largest. As such, Germany is the key driver for Compumedics’ future growth in Europe, having over 300 accredited sleep clinics and a market potential of about USD36 million per annum. The winning of these additional contracts confirms Compumedics’ strategic advancement in developing Europe as a principal market for the Company, and the Company’s continued focus on key global markets.

The establishment of the German business follows the development of the Company’s USA direct-sales business, now responsible for approximately 40% of the Company’s annual sales of about $40m per annum. Revenues in the USA have grown from about USD1 million in 2000 to USD13 million in 2008, representing year-on-year growth of approximately 40%.

For Further information: Mr David Burton Executive Chairman, CEO Phone: + 61 3 8420 7300 Fax: +61 3 8420 7399

Mr David Lawson Chief Financial Officer Phone: + 61 3 8420 7300 Fax: +61 3 8420 7399

Investor Relations & Media Enquires:

Mr Rod North Executive Director Bourse Communications Pty Ltd Phone: +61 3 9510 8309 Mobile: +61 (0) 408 670 706

Compumedics Limited (ASX:CMP)

Released on 15 June, 2009 Page 1 of 2

About Compumedics Compumedics Limited, founded in 1987, is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In 1987 Compumedics established Asia Pacific’s first fully computerised sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices. In 1995 the company was selected to supply equipment to the US Sleep Heart Health Study, the world’s largest sleep study of its kind, currently exceeding 14,000 studies with 20,000 patients scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe the products are distributed in over 50 countries. In 1998 Compumedics was awarded the overall Australian Exporter of the Year. In 2000 Compumedics was listed on the Australian Stock Exchange. In 2002 , Compumedics acquired US-based Neuroscan - the world's leading supplier of instruments for brain-research. In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. In 2003 Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. In 2004 , Compumedics acquired German-based DWL Elektronishe GmbH, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. In 2006 , Compumedics was awarded the Frost and Sullivan Technology Leadership award for the innovative Somté recorder product. In 2007 , Compumedics and Chairman were inducted into the Victorian Manufacturing Hall of Fame. In 2008 the DWL division received the top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics the Compumedics sales have grown more than 4 fold from $9 million (1999) to $39 million (2008). www.compumedics.com

Compumedics Limited (ASX:CMP)

Released on 15 June, 2009 Page 2 of 2